Lung Cancer
FDA Approves Hernexeos for Non-Squamous NSCLC with HER2 TKD Activating Mutations
The FDA granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim), for adults with unresectable or metastatic non-squamous NSCLC whose tumors have HER2 tyrosine kinase domain activating mutations.
AUGUST 10, 2025
FDA Grants Accelerated Approval to Zegfrovy for Some Patients With Metastatic NSCLC
The FDA granted accelerated approval to sunvozertinib (Zegfrovy, Dizal [Jiangsu] Pharmaceutical) for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
JULY 2, 2025
FDA Grants Accelerated Approval to Datroway for Some Patients With EGFR-Mutated NSCLC
The FDA granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo) for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.
JUNE 24, 2025
FMT May Boost Immunotherapy Effectiveness, Overuse of Antibiotics Would Not
Fecal microbiota transplantation may enhance the effectiveness of immunotherapies by reducing gut dysbiosis, according to a presentation at the 2025 ASCO Annual Meeting.
JUNE 16, 2025
FDA Approves Ibtrozi for ROS1-Positive NSCLC
The FDA approved taletrectinib (Ibtrozi, Nuvation Bio), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
JUNE 11, 2025
FDA Grants Accelerated Approval to Emrelis for NSCLC With High C-Met Protein Overexpression
The FDA granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie), a c-Met−directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (≥50% of tumor cells with strong [3+] staining), as determined by an FDA-approved test, who have received a prior systemic therapy.
MAY 20, 2025
High Rates of Polypharmacy Among Lung Cancer Patients—Even Younger Adults
Polypharmacy is highly prevalent among adults with cancer and multimorbidity, and is associated with high health service utilization even among younger adults.
MARCH 12, 2025
Signals From Lungs of Cancer Patients May Cause Thrombosis
Blood clots appear to form in response to signals from the lungs of cancer patients—not from other organ sites, as previously thought, according to a preclinical multicenter study.
MARCH 3, 2025
Managing Respiratory Distress Symptoms in People with Lung Cancer
Integrating non-pharmacological interventions with pharmacological management of lung respiratory distress symptoms is essential.
FEBRUARY 21, 2025
Breakthrough in EGFR-Mutated NSCLC: Rybrevant Plus Lazcluze Extends Overall Survival
The bispecific antibody amivantamab-vmjw (Rybrevant, Janssen/Johnson & Johnson) plus lazertinib (Lazcluze, Janssen/J&J) significantly extended overall survival in patients with locally advanced or metastatic non-small cell lung cancer with certain epidermal growth factor receptor mutations, according to new top-line results from the phase 3 MARIPOSA study.
JANUARY 17, 2025
FDA Approves Ensacove for ALK-Positive Locally Advanced or Metastatic NSCLC
The FDA approved ensartinib (Ensacove, Xcovery Holdings) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK inhibitor.
DECEMBER 19, 2024
FDA Approves Imfinzi for Limited-Stage Small Cell Lung Cancer
The FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
DECEMBER 5, 2024